Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/103971| Title: | Molecular profiling of breast cancer intra-tumour heterogeneity |
| Other Titles: | PS-04-002 Molecular profiling of breast cancer intra-tumour heterogeneity |
| Authors: | Baldacchino, S. Borg, E. Scerri, J. DeGaetano, J. Saliba, C. Scerri, C. Schembri Wismayer, P. Grech, Godfrey |
| Keywords: | Breast -- Cancer -- Molecular aspects Breast -- Cancer -- Chemotherapy Drug resistance in cancer cells HER-2 protein Trastuzumab |
| Issue Date: | 2019 |
| Publisher: | Springer |
| Citation: | Baldacchino, S., Borg, E., Scerri, J., DeGaetano, J., Saliba, C., Scerri, C.,...Grech, G. (2019). Molecular profiling of breast cancer intra-tumour heterogeneity. Virchows Archiv, 475 (Suppl. 1), S96-S96. |
| Abstract: | Background & Objectives: Despite the efficacy of targeted therapy, some HER2 positive breast cancer patients do not respond to trastuzumab with an 88% 4-year overall survival (n=43). A death rate of 12% persists at 15 years from diagnosis of patients on tamoxifen for 10 years. Tumour heterogeneity is a known mechanism for resistance. Understanding heterogeneity allows for combinatorial targeted therapies to target the distinct tumour clones and achieve remission. |
| URI: | https://www.um.edu.mt/library/oar/handle/123456789/103971 |
| Appears in Collections: | Scholarly Works - FacM&SPat |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Molecular profiling of breast cancer intra tumour heterogeneity 2019.pdf Restricted Access | 94.04 kB | Adobe PDF | View/Open Request a copy |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.